ArticleCase reports in critical care2026
Use of Double Dose Intravenous Immunoglobulin Therapy in the Treatment of Streptococcal Toxic Shock Syndrome.
Article in Case reports in critical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Use of Double Dose Intravenous Immunoglobulin Therapy in the Treatment of Streptococcal Toxic Shock Syndrome.Case reports in critical care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Streptococcal toxic shock syndrome (STSS) is a life-threatening condition with increasing incidence and high mortality worldwide. It is characterised by hypotension and multiorgan failure, resultant of invasive group A Streptococcus (GAS) infections. Intravenous immunoglobulin (IVIG) has been proposed as an adjunctive therapy that reduces mortality in patients with STSS, and is thought to exert its effects by neutralising streptococcal superantigens and exotoxins to modulate the host immune response. Currently, there is a paucity of knowledge about the efficacy of repeated dosing if patients remain unstable after the first dose of IVIG. In this report, we describe the case of a woman in her 60s with STSS and meningoencephalitis, who demonstrated an improvement in haemodynamic status after the first dose of IVIG, but subsequently had rebound of hypotension and high vasopressor requirements, which resolved after a second dose of IVIG. This case highlights the potential need for repeated dosing of IVIG in STSS, in situations where an initial improvement in haemodynamic status is followed by deterioration.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.